Rami Levin - 01 Jan 2026 Form 4 Insider Report for CNS Pharmaceuticals, Inc. (CNSP)

Reporting relationship: CEO and President, Director
Issuer ticker: CNSP
Reported as of: 01 Jan 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 02 Jan 2026, 17:01:02 UTC
Source filing: View source filing
Reporting owner signature: Christopher Downs, Attorney-in-Fact

Key filing fact

Rami Levin filed Form 4 for CNS Pharmaceuticals, Inc. (CNSP) on 02 Jan 2026.

Key facts

This page summarizes Rami Levin's Form 4 filing for CNS Pharmaceuticals, Inc. (CNSP).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 02 Jan 2026, 17:01.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002102719 Primary reporting owner

Levin Rami

Relationship: CEO and President, Director
Address: C/O CNS PHARMACEUTICALS, INC., 100 WEST LOOP SOUTH, SUITE 900, HOUSTON
Signature: Christopher Downs, Attorney-in-Fact
Signature date: 02 Jan 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CNSP transaction Derivative

Restricted Stock Units

Award

Transaction value
Shares: +19,000
Change %
Price
Shares after: 19,000
Date: 01 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 19,000
Exercise price
Footnotes: F1, F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Each restricted stock unit represents a contingent right to receive one share of Company common stock.

Footnote F2

The restricted stock units set forth in the table vest as follows: 25% on the six-month anniversary of the transaction date, 25% on the twelve-month anniversary of the transaction date, and the remaining 50% in twelve quarterly installments thereafter, subject to the reporting person's continued employment on each vesting date.

Footnote F3

Issued in connection with the reporting person's employment with the Company.